Why Serina Therapeutics, Inc.’s (SER) Stock Is Down 5.24%
As of Monday, November 03, Serina Therapeutics, Inc.’s SER share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Commentary & Analysis
Why Serina Therapeutics, Inc.’s (SER) Stock Is Up 5.23%
As of Wednesday, October 08, Serina Therapeutics, Inc.’s SER share price has surged by 5.23%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Serina Therapeutics, Inc.’s (SER) Stock Is Down 5.78%
As of Wednesday, September 10, Serina Therapeutics, Inc.’s SER share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Serina Therapeutics, Inc.’s (SER) Stock Is Up 5.26%
As of Friday, August 29, Serina Therapeutics, Inc.’s SER share price has surged by 5.26%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Serina Therapeutics, Inc.’s (SER) Stock Is Down 6.19%
As of Wednesday, August 27, Serina Therapeutics, Inc.’s SER share price has dipped by 6.19%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | SER | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $69.3 | $282.4 | 18% |
|
| Shares Out (Mil) | 16.4 | 54.0 | 27% |
|
| Institutional Ownership | 12.3% | 93.1% | 7% |
|
| Float (Mil) | 11.1 | 42.2 | 20% |
|
| Beta | 0.00 | 0.94 | 6% |
|
| Avg Daily Volume (000s) | 31 | 482 | 25% |
|
| Price Change (52-week) |
(48.3%) | 59.9% | 15% |
|
| Growth | SER | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.350) | ($1.410) | ($1.050) | |
| Month Ago EPS | ($0.350) | ($1.410) | ($1.050) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.350) | ($1.410) | ($1.050) | |
| Year/Year Chg | (35.8%) | (26.1%) | (52.8%) | |
| Financials | SER | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($21) | ($43) | 23% |
|
| EPS (TTM) | ($1.935) | ($1.500) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | $17 | $2 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $45 | $190 | 15% |
|
| Valuation | SER | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.69 | 2.84 | 70% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SER | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (121.9%) | (47.7%) | 4% |
|
| ROE | (271.6%) | (55.0%) | 3% |
|
| Liabilities to Assets | 27.4% | 29.8% | 19% |
|
| F-Score | 3 | 3 | 18% |
|
Serina Therapeutics, Inc. did not pass any screens on 9/4/2026.
